Mild Cognitive Impairment (MCI)
Conditions
Interventions
MCTs+DHA intervention group:MCTs solid drinks (1 bag/day, 14g C8+10g C10/bag) and DHA capsules (2 capsules/day, 400mg/capsule), oral, 12 months
MCTs intervention group:MCTs solid drinks (1 bag/day, 14g C8+10g C10/bag) and DHA placebo (2 capsules/day), oral, 12 months
DHA intervention group:MCTs placebo (1 bag/day) and DHA capsules (2 capsules/day, 400mg/capsule), oral, 12 months
control group:MCTs placebo (1 bag/day) and DHA placebo (2 capsules/day), oral, 12 months
Sponsors
School of Public Health, Tianjin Medical University
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The age is greater than or equal to 65; 2. Subjectively self-reported or objectively diagnosed with symptoms of cognitive decline such as memory loss for 6 months; 3. The score of cognitive ability measured by MMSE Chinese version is lower than the standard threshold by age and education level; 4. Normal or slightly decreased ability of daily living: score of activity of daily living (ADL) = 18 points; 5. Does not meet the diagnostic criteria for dementia.
Exclusion criteria
Exclusion criteria: 1. The neurological examination showed signs of focal central nervous disorders such as hemiplegia, hemisensory disturbance, aphasia, history of cerebrovascular diseases (including hemorrhagic and ischemic), and internal brain injury or fracture; 2. Respiratory bronchitis, severe hypertension, angina pectoris, severe infection and other medical diseases; 3. History of psychotic patients with obvious depression, anxiety, and other endocrine system diseases (such as hyperthyroidism, hypothyroidism, systemic lupus erythematosus, rheumatoid arthritis, etc.); 4. Newly discovered, advanced or advanced tumors; 5. Visual and auditory impairment or language communication difficulties that significantly affect the cognitive function test; 6. History of alcohol dependence and abuse of other psychoactive substances (such as antipsychotics, benzodiazepines, etc.), or taking drugs that affect cognitive function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cognitive function (full intelligence quotient);medium-chain fatty acid;docosahexaenoic acid;ketone body; | — |
Secondary
| Measure | Time frame |
|---|---|
| inflammatory factor;mitochondrial function in leukocyte;glucose in blood;the expression of ApoE gene; | — |
Countries
China
Contacts
Public ContactGuowei Huang
School of Public Health, Tianjin Medical University
Outcome results
None listed